Shalby reports strong Q2 FY26 revenue and profit growth

Shalby Limited reported consolidated revenue of INR289 crore for Q2 FY26, a 5.5% increase year-on-year from INR274 crore. Consolidated EBITDA rose by 15.8% to INR46.1 crore, up from INR39.8 crore, with the EBITDA margin improving to 15.9% from 14.5%. Consolidated profit before tax (PBT) saw a substantial 39.2% growth, reaching INR19.1 crore compared to INR13.7 crore previously, pushing the PBT margin to 6.6% from 5%.

The company's consolidated profit after tax (PAT) grew by approximately 200% year-on-year, from INR2.4 crore to INR7.3 crore, with the PAT margin increasing to 2.5% from 0.9%. Stand-alone revenue also increased by 5.6% year-on-year to INR230 crore in Q2 FY26. Operational metrics showed ARPOB growing 5.2% year-on-year to INR40,794, while the number of occupied beds decreased by 2.5% to 673, resulting in an occupancy rate of 48%.

Shalby MedTech, the medical implant business, saw its consolidated revenue for Q2 FY26 surge by 42.1% year-on-year to INR33.7 crore. The segment achieved a consolidated EBITDA of INR3.66 crore, a significant improvement from a negative INR21.6 lakhs in Q2 FY25. The company also announced strategic initiatives including the introduction of robotic technology, a marketing strategy overhaul for Shalby International Hospital, and new product development efforts to drive future growth.